Cargando…
Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients
BACKGROUND AND AIMS: Chronic hepatitis C (HCV) is a liver disease affecting over 3 million Americans. Liver biopsy is the gold standard for assessing liver fibrosis and is used as a benchmark for initiating treatment, though it is expensive and carries risks of complications. FibroTest is a non-inva...
Autores principales: | Liu, Shan, Schwarzinger, Michaël, Carrat, Fabrice, Goldhaber-Fiebert, Jeremy D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229483/ https://www.ncbi.nlm.nih.gov/pubmed/22164204 http://dx.doi.org/10.1371/journal.pone.0026783 |
Ejemplares similares
-
Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States
por: Liu, Shan, et al.
Publicado: (2013) -
Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus
Infection in Non-VA and VA Populations
por: Liu, Shan, et al.
Publicado: (2016) -
Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis
por: Goldhaber-Fiebert, Jeremy D., et al.
Publicado: (2023) -
Estimating the cost of cervical cancer screening in five developing countries
por: Goldhaber-Fiebert, Jeremy D, et al.
Publicado: (2006) -
Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence
por: Cipriano, Lauren E., et al.
Publicado: (2018)